Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
Launched by BEIGENE · Nov 14, 2019
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
For the purposes of this study, "study treatment" will refer to all investigational agents. A parent study is defined as the original BeiGene-sponsored clinical trial in which the participant was initially enrolled and received BeiGene investigational drugs (with or without other treatments).
Gender
ALL
Eligibility criteria
- Key Inclusion Criteria:
- • 1. Currently participating in a BeiGene-sponsored eligible parent study
- • 2. Fulfills treatment criteria specified in the parent study protocol
- • 3. In the opinion of the investigator, the participant will continue to benefit from and tolerate any of the parent study treatments.
- 4. The first dose of study treatment in the LTE study will be received within the treatment interruption period allowed by the parent study:
- • 1. "Treatment interruption" (unplanned pause in study treatment) and "treatment break" (planned stop of study therapy) are not interchangeable. Restarting study treatment beyond the interruption period allowed by the parent study or after a treatment break will be determined by the investigator and the sponsor. Participants who have not restarted treatment within 1 year of starting a treatment break must discontinue treatment.
- Specific Inclusion Criteria for Participants Who Continue Survival Follow-up Only in the Extension Study:
- • 1. Currently participating in a BeiGene-sponsored eligible parent study in the survival follow-up portion
- • 2. Parent study plans to have survival analysis
- Key Exclusion Criteria:
- • 1. Permanently discontinued from all investigational drugs in the parent study due to unacceptable toxicity, noncompliance with study procedures, or withdrawal of consent
- • 2. Have uncontrolled active systemic infection or recent infection requiring parenteral antimicrobial therapy prior to the start of the extension study
- • 3. Have a life-threatening illness, medical condition, or organ system dysfunction that in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of investigational drugs, or put the study outcomes at undue risk
- • 4. Underwent treatment with any systemic anticancer treatment (other than treatment permitted in the parent study) during the time between the last treatment in the parent study and the first dose of study treatment in the LTE study
- • 5. Pregnant or lactating women
- • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
About Beigene
BeiGene is a global biotechnology company focused on discovering, developing, and commercializing innovative medicines for the treatment of cancer. With a robust pipeline of targeted therapies and immuno-oncology agents, BeiGene is dedicated to advancing precision medicine to improve patient outcomes. The company integrates cutting-edge research, clinical development, and manufacturing capabilities to deliver transformative therapies across diverse oncology indications. Committed to addressing unmet medical needs, BeiGene collaborates with healthcare professionals and institutions worldwide to accelerate the development of its product candidates and enhance the lives of patients battling cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami Beach, Florida, United States
Seoul, , Korea, Republic Of
Clichy, , France
Randwick, New South Wales, Australia
Woodville South, South Australia, Australia
Dallas, Texas, United States
Woodville, South Australia, Australia
Auckland, , New Zealand
Kuala Lumpur, , Malaysia
Waratah, New South Wales, Australia
Taichung, , Taiwan
Tainan, , Taiwan
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Kuching, , Malaysia
Auckland, , New Zealand
Melbourne, Victoria, Australia
Nanjing, Jiangsu, China
Jinan, Shandong, China
Guangzhou, Guangdong, China
Dallas, Texas, United States
Changchun, Jilin, China
Lyon, , France
Hangzhou, Zhejiang, China
Zhengzhou, Henan, China
Hangzhou, Zhejiang, China
Guangzhou, Guangdong, China
Zhuhai, Guangdong, China
Chengdu, Sichuan, China
Dalian, Liaoning, China
South Brisbane, Queensland, Australia
Changsha, Hunan, China
Fuzhou, Fujian, China
Zhengzhou, Henan, China
Guangzhou, Guangdong, China
Zhengzhou, Henan, China
Beijing, Beijing, China
Shanghai, Shanghai, China
Tianjin, Tianjin, China
Shanghai, Shanghai, China
Seoul, , Korea, Republic Of
Xuzhou, Jiangsu, China
Shanghai, Shanghai, China
Nanchang, Jiangxi, China
Harbin, Heilongjiang, China
Changchun, Jilin, China
Kaohsiung, , Taiwan
Tainan, , Taiwan
Jinan, Shandong, China
Guangzhou, Guangdong, China
Xiamen, Fujian, China
Terni, , Italy
Beijing, Beijing, China
Beijing, Beijing, China
St Leonards, New South Wales, Australia
Chongqing, Chongqing, China
Shanghai, Shanghai, China
Hangzhou, Zhejiang, China
Clayton, Victoria, Australia
Wuhan, Hubei, China
Changchun, Jilin, China
Wuhan, Hubei, China
Hangzhou, Zhejiang, China
Beijing, Beijing, China
Hefei, Anhui, China
Shenyang, Liaoning, China
Taoyuan, , Taiwan
Changsha, , China
Nanning, Guangxi, China
Taichung City, , Taiwan
Guangzhou, Guangdong, China
Adana, , Turkey
Tekirdag, , Turkey
Goyangsi, Gyeonggi Do, Korea, Republic Of
Chiayi, , Taiwan
Taoyuan, , Taiwan
Brisbane, Queensland, Australia
Incheon, , Korea, Republic Of
Shantou, Guangdong, China
Taiyuan, Shanxi, China
Fuzhou, Fujian, China
Xuzhou, Jiangsu, China
Beijing, Beijing, China
South Brisbane, Queensland, Australia
Tianjin, Tianjin, China
Changchun, Jilin, China
Tianjin, Tianjin, China
Wuhan, , China
Wuhan, Hubei, China
Wuhan, Wuhan, China
Xuzhou, Jiangsu, China
Guangzhou, Guangdong, China
Shenyang, Liaoning, China
Wuhan, Hubei, China
Baoding, Hebei, China
Hefei, Anhui, China
Wuhan, Hubei, China
Tianjin, Tianjin, China
Shanghai, Shanghai, China
Hangzhou, Zhejiang, China
Guangdong, Guangzhou, China
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Dalian, Liaoning, China
Xi'an, Shanxi, China
Saint Leonards, New South Wales, Australia
East Melbourne, Victoria, Australia
Beijing, Beijing, China
Beijing, Beijing, China
Harbin, Heilongjiang, China
Yangzhou, Jiangsu, China
Taipei, , Taiwan
Haikou, Hainan, China
Changzhou, Jiangsu, China
Zhuhai, Guangdong, China
Bangkok, , Thailand
Urumqi, Xinjiang, China
New York, New York, United States
Nanchang, Jiangxi, China
Nice, , France
Seongnamsi, Gyeonggido, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Guangzhou, Guangdong, China
Wenzhou, Zhejiang, China
Hangzhou, Zhejiang, China
Nashville, Tennessee, United States
Nantes Cedex, , France
Bologna, , Italy
Pisa, , Italy
Chibashi, Chiba, Japan
Chuoku, Tokyo, Japan
Gdynia, , Poland
Guangzhou, Guangdong, China
Zuiyi, Guizhou, China
Wuhan, Hubei, China
Xian, Shaanxi, China
Weifang, Shandong, China
Chengdu, Sichuan, China
Clichy, , France
Montpellier, , France
Goyangsi, Gyeonggido, Korea, Republic Of
Stanbulbakrkoy, , Turkey
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Sapporoshi, Hokkaido, Japan
Taichung City, , Taiwan
Akitashi, Akita, Japan
Fukuokashi, Fukuoka, Japan
Gyeonggido, Gyeonggi Do, Korea, Republic Of
Seongnamsi, Gyeonggi Do, Korea, Republic Of
Suwonsi, Gyeonggi Do, Korea, Republic Of
Hwasungun, Jeollanam Do, Korea, Republic Of
Suwonsi, Gyeonggi Do, Korea, Republic Of
Warszawa, , Poland
Guangzhou, Guangdong, China
Chengdu, Sichuan, China
Suitashi, Osaka, Japan
Izumishi, Osaka, Japan
Goyangsi, Gyeonggi Do, Korea, Republic Of
Istanbulbakrkoy, , Turkey
Guishan Dist, , Taiwan
North Dist, , Taiwan
Nashville, Tennessee, United States
Dallas, Texas, United States
Miami Beach, Florida, United States
New York, New York, United States
Nantes, , France
Nice, , France
Suitashi, Osaka, Japan
Bundanggu Seongnamsi, Gyeonggi Do, Korea, Republic Of
Bundanggu Seongnamsi, Gyeonggi Do, Korea, Republic Of
Ilsandonggu Goyangsi, Gyeonggi Do, Korea, Republic Of
Paldalgu Suwonsi, Gyeonggi Do, Korea, Republic Of
Namdonggu, , Korea, Republic Of
Dongjakgu, Seoul Teugbyeolsi, Korea, Republic Of
Gangnamgu, Seoul Teugbyeolsi, Korea, Republic Of
Gurogu, Seoul Teugbyeolsi, Korea, Republic Of
Seochogu, Seoul Teugbyeolsi, Korea, Republic Of
Seodaemungu, Seoul Teugbyeolsi, Korea, Republic Of
Songpagu, Seoul Teugbyeolsi, Korea, Republic Of
Suwonsi, , Korea, Republic Of
Warszawa, , Poland
Niaosong Dist, , Taiwan
North Dist, , Taiwan
Yongkang Dist, , Taiwan
Pathum Wan, , Thailand
Kurukopru, , Turkey
Namdonggu, Incheon Gwang'yeogsi, Korea, Republic Of
Patients applied
Trial Officials
Study Director
Study Director
BeiGene
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials